Evidence map›Paper›PMID 34091757›Full record

ArticleActa diabetologica2021

Silencing lncRNA GAS5 alleviates apoptosis and fibrosis in diabetic cardiomyopathy by targeting miR-26a/b-5p.

Chunping Zhu, Haijun Zhang, Dongmei Wei, Zhe Sun

Abstract read
PubMed Publisher
In one paragraph

Article in Acta diabetologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. The role of lncRNA-mediated pyroptosis in cardiovascular diseases.Frontiers in cardiovascular medicine · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Chunping ZhuDepartment of Cardiac Function, The First Hospital of Qiqihar & Affiliated Qiqihar Hospital, Southern Medical University, Qiqihar, 161005, Heilongjiang, People's Republic of China.
Haijun ZhangThe Second Department of Endocrinology, The First Hospital of Qiqihar & Affiliated Qiqihar Hospital, Southern Medical University, No. 30 Park Road, Longsha, Qiqihar, 161005, Heilongjiang, People's Republic of China. haijunzhangqiqihar@163.com.ORCID http://orcid.org/0000-0001-6064-1836
Dongmei WeiDepartment of Traditional Chinese Medicine Geriatrics, The First Hospital of Qiqihar & Affiliated Qiqihar Hospital, Southern Medical University, Qiqihar, 161005, Heilongjiang, People's Republic of China.
Zhe SunThe Second Department of Endocrinology, The First Hospital of Qiqihar & Affiliated Qiqihar Hospital, Southern Medical University, No. 30 Park Road, Longsha, Qiqihar, 161005, Heilongjiang, People's Republic of China.
Southern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLncRNA GAS5 is associated with high glucose-induced cardiomyocyte injury, but its role in diabetic cardiomyopathy (DCM) remains unclear.

methodsMice were administered with streptozotocin to construct the diabetic model (DM). Primary mouse cardiomyocytes were isolated and treated with 30 mmol/L high glucose to mimic the diabetic condition in vitro. GAS5 expression was detected by quantitative reverse transcription polymerase chain reaction. The relationship between GAS5 and miR-26a/b-5p was determined by bioinformatic prediction, luciferase reporter assay and RNA immunoprecipitation assay. The cardiac function of diabetic mice was evaluated by two-dimensional echocardiography.

resultsGAS5 was significantly upregulated in diabetic cardiomyopathy both in vitro and in vivo. GAS5 knockdown and miR-26a/b-5p overexpression not only effectively attenuated myocardial fibrosis of diabetic mice in vivo but also inhibited high glucose-induced cardiomyocyte injury in vitro. miR-26a/b-5p was identified as a target of GAS5. GAS5 knockdown efficiently attenuated myocardial fibrosis and high glucose-induced cardiomyocyte injury through negatively regulating miR-26a/b-p.

conclusionOur study showed that GAS5 promotes DCM progression by regulating miR-26a/b-5p, suggesting that GAS5 might be a potential therapeutic target for DCM.

Indexed as

Diabetes Mellitus, ExperimentalDiabetic CardiomyopathiesMicroRNAsRNA, Long NoncodingAnimalsApoptosisFibrosisMiceMicroRNAsRNA, Long NoncodingApoptosisDiabetic cardiomyopathyGAS5MiR-126a-5pMiR-126b-5p

Identifiers

PMID34091757
OpenAlexW3167722710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.